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Purpose: Chronic obstructive pulmonary disease (COPD) patients may suffer from poor sleep 
and health-related quality of life. We hypothesized that disturbed sleep in COPD is correlated 
with quality of life.
Methods: In 180 patients with COPD (forced expired volume in 1 second [FEV1] 47.6 ± 15.2% 
predicted, 77.8% male, aged 65.9 ± 11.7 years), we administered general (Health Utilities 
Index 3) and disease-specific (St George’s Respiratory) questionnaires and an index of disturbed 
sleep (Pittsburgh Sleep Quality Index).
Results: Overall scores indicated poor general (Health Utilities Index 3: 0.52 ± 0.38), 
  disease-specific (St George’s: 57.0 ± 21.3) quality of life and poor sleep quality (Pittsburgh 
11.0 ± 5.4). Sleep time correlated with the number of respiratory and anxiety symptoms reported 
at night. Seventy-seven percent of the patients had Pittsburg scores .5, and the median Pittsburgh 
score was 12. On multivariate regression, the Pittsburgh Sleep Quality Index was an independent 
predictor of both the Health Utilities Index 3 and the St George’s scores, accounting for 3% and 
5%, respectively, of the scores. Only approximately 25% of the patients demonstrated excessive 
sleepiness (Epworth Sleepiness Scale .9).
Conclusions: Most patients with COPD suffer disturbed sleep. Sleep quality was correlated 
with general and disease-specific quality of life. Only a minority of COPD patients complain 
of being sleepy.
Keywords: COPD, quality of life, Pittsburgh Sleep Quality Index, St George’s Respiratory 
Questionnaire, Health Utilities Index, sleep quality
Introduction
In chronic obstructive pulmonary disease (COPD), symptom burden is more closely 
related to health-related quality of life (HrQOL) than to forced expired volume in one 
second (FEV1).1–3 It is now accepted that HrQOL is an important endpoint for clinical 
trials in COPD.4,5
Poor sleep quality influences HrQOL in COPD.6 Physiologic changes in COPD 
lead to fragmented sleep, including nocturnal airflow obstruction, arterial oxygen 
desaturation, hypercapnia, and use of accessory muscles of respiration.6,7 Patients with 
COPD frequently complain of difficulty initiating and maintaining sleep and increased 
number of arousals during sleep.8–10 Indeed, data from two recent small studies indicate 
that poor sleep quality is a correlate of HrQOL in COPD.11,12 To date, however, there 
are few studies detailing the relationship between sleep quality and HrQOL in COPD. 
Also, there are few studies accounting for effects of socioeconomic factors, comorbidity 
burden, and medication use on COPD and sleep-related HrQOL.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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We performed a cross-sectional study of HrQOL on a 
convenience sample of stable COPD patients coming to the 
pulmonary clinic for routine follow-up visits, incorporating 
different metrics of HrQOL: demographic, physiologic, and 
socioeconomic information; medication use; and comorbid-
ity burden. We wished to characterize the extent of sleep 
disturbances in patients with COPD. Further, we wished 
to determine predictors of HrQOL from among commonly 
measured variables and the contribution of sleep disturbance 
to HrQOL. We hypothesized that sleep disturbances would 
be independent predictors of HrQOL in COPD.
Methods
The study was performed at the Pulmonary Clinic of the 
Soroka University Medical Center, Beer Sheva, Israel, 
  following approval by the Ethics Committee.
This exploratory study included a four-week recall 
  questionnaire, spirometry, and abstraction of additional 
patient specific data from the patients’ major health 
maintenance organization data files. In this study,   inclusion 
criteria were: 1) age .35 years; 2) smoking $10   pack-years; 
3) pulmonologist-diagnosed COPD based on history of 
smoking, airflow obstruction on spirometry, and the   presence 
of at least one symptom of COPD (ie,   exercise-limiting 
  dyspnea, chronic cough, sputum production); 4) no exac-
erbations within one month; and 5) no hospitalization/
urgent care visits within one month. Exclusion criteria 
were: 1) other major pulmonary diagnoses; or 2) disease 
expected to shorten life span to ,3 years. Spirometry was 
performed on the day of questionnaire administration and 
included forced vital capacity (FVC) and FEV1. Severity was 
staged according to the Global Initiative for Obstructive Lung 
Disease (GOLD).14
The four-week recall questionnaire included validated 
scales, additional symptom questions, and demographic 
and socioeconomic information. Hebrew translations of 
specific scales were validated.15 These included: 1) Health 
Utilities Index 3 (HUI3),16–18 a generic index rating health 
from 0 (very ill) to 1 (perfect health) where scores of less 
than 0 are allowed (quality of life rated as worse than death); 
2) St George’s Respiratory Questionnaire (SGRQ),19,20 a scale 
of COPD-specific quality of life ranging from 0% (best) to 
100% (worst); 3) Pittsburgh Sleep Quality Index (PSQI),21 
an index of self-rated quality of sleep, with scores from 
0 to 21, with increasing score meaning worse sleep quality 
and a score of .5 indicating poor sleep; and 4) Epworth 
Sleepiness Scale (ESS)22 rating sleepiness from 0 (none) to 
24 (worst), with scores .9 indicating excessive sleepiness. 
In addition to these, we asked questions on the frequency of 
specific nocturnal respiratory and anxiety symptoms using 
a survey entitled Sleep Symptom Questionnaire (Figure 1). 
There is no composite score. Demographics included age, 
gender, body mass index (BMI), smoking status (current, 
ex-smoker), and pack-years smoking. Socioeconomic status 
included: 1) income relative to the Israeli average; 2) years 
of schooling; 3) employment status; and 4) marital status. 
Questionnaires were administered by trained interviewers.
One hundred seventy-seven of the patients were members 
of the Clalit Health Services, the largest health maintenance 
organization in Israel. For these patients, we reviewed the 
Clalit database to obtain information on medication use within 
the quarter prior to the administration of the questionnaire and 
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Figure 1 Sleep Symptom questionnaire.
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the presence of concomitant obstructive sleep apnea (OSA). 
Data on concomitant comorbidities were gathered to allow 
calculation of the age-adjusted Charlson Comorbidity Score 
with Deyo modification (CCI).24–27
Data analysis
Data were expressed as mean (standard deviation [SD]) and 
median (25%–75%). Bivariate associations were assessed 
using Pearson product-moment coefficients and least-squares 
regression. Backwards stepwise multivariate regression was 
used to determine independent effects of significant bivariate 
predictors. Differences between means were tested using 
unpaired t-tests. Rates and proportions were tested using Chi-
square analysis. The null hypothesis was rejected at the 5% 
level. Differences in indices of HrQOL with different levels 
of COPD severity (according to GOLD) were tested using 
one-factor analysis of variance (ANOVA). Data analysis was 
performed using Statistical Package for the Social   Sciences, 
version 17 (SPSS Inc, Chicago, IL, USA) or GBstat v9 
(Dynamic Microsystems Inc, Silver Spring, MD, USA).
Results
Two hundred stable COPD patients were approached 
sequentially when they came in for routine clinic appoint-
ments. Twenty of these refused participation or had insufficient 
knowledge of the Hebrew language to take the questionnaires. 
Table 1 shows spirometric, demographic, and socioeconomic 
data. Data were not available for arterial blood gases when 
stable in this cohort. Data were available for 164 of the patients 
on room air oxygen saturation, taken the same time as the 
spirometry. This information is also presented in Table 1. Most 
patients were older than 60 years, ranked their income as less 
than the Israeli average, were on a pension, were male, were 
past smokers, and had COPD deemed “severe” or “very severe” 
according to GOLD classification. HrQOL ratings, whether 
general or specific, were poor (Table 2). The mean PSQI was 
high, indicating self-rated poor sleep quality. The majority 
of patients rated sleep as abnormal (PSQI . 5). On the other 
hand, only a minority of respondents rated daytime sleepiness 
as abnormal (ESS . 9). Twenty-seven of our patients carried 
the diagnosis of OSA. We had no data on severity of OSA, 
nor did we have continuous positive airway pressure (CPAP) 
treatment or compliance rates. However, as there were no 
differences in any reported metric or HrQOL score between 
patients with and without OSA (data not shown), we have 
retained the patients with known OSA in the analysis.
Sleep quality
Table 3 lists some specific sleep symptoms from answers on the 
PSQI. The median self-reported sleep time was only five hours 
Table 1 Demographics and spirometric data (n = 180)
Variable Mean (SD) or proportion (%) Median (25%–75%)
Age (yrs) 65.9 (11.7) 66.7 (59.5–73.2)
BMI (kg/m2) 27.3 (5.5) 26.6 (23.5–30.1)
Pack-yrs smoking 49.1 (29.5) 40.0 (27.0–60.0)
Years of education 9.24 (5.43) 10 (6–12)
FVC (L) 2.17 (0.7) 2.16 (1.64–2.61)
FVC (% pred) 64.7 (16.3) 66.0 (52–75)
FeV1 (L) 1.24 (0.50) 1.18 (0.88–1.53)
FeV1 (% pred) 47.6 (15.2) 46 (36–58)
FeV1/FVC (%) 57.5 (12.3) 58.7 (50.2–65.3)
Baseline O2 saturation (%)  95.0 (2.9) 96.0 (94%–97%)
CCI 6.63 (3.52) 6 (4–9)
number of medications (all) 4.6 (2.2) 5 (3–6)
number of pulmonary 
medications (not including 
systemic steroids)
2.0 (1.1) 2 (1–3)
Males  140 (77.8%)
Current smokers 43 (28.9%)
earn less than average 
income (8000 nIS/month)
135 (80.3%)
On pension 126 (72.4%)
Currently married 136 (76.4%)
gOLD class  Mild (1) Moderate (2) Severe (3) Very severe (4)
19 (10.6%) 55 (30.6%) 83 (46.1%) 23 (12.8%)
Abbreviations: BMI, body mass index (kg/m2); CCI, Charlson Comorbidity Index; gOLD, global initiative for chronic obstructive lung disease; FVC, forced vital capacity; 
FVC%, FVC% predicted; FeV1, forced expired volume in one second; FeV1%, FeV1 as percent predicted.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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and the median latency to sleep was 30 minutes. The patients 
reported a median time in bed of approximately eight hours.
Self-reported respiratory symptoms were fairly   common 
ranging from 48% to 74% of the patients. Looking at sleep 
apnea symptoms, snoring, witnessed apneas (by bed 
  partner), and sleepiness, 31.8% reported frequent ($3 times 
per week) snoring, 21.5% witnessed apneas at night, but 
only 6.7% reported sleepiness interfering with daily activi-
ties. As a   surrogate for possible sleep apnea,23 we found that 
41% reported severe snoring and/or witnessed apneas.
nocturnal symptoms and sleep quality
Nocturnal wheezing, worrying, and uncontrolled thoughts 
were associated with low sleep times (Table 4). Other 
  specific respiratory symptoms, although common, were not 
significantly associated with sleep times, including cough, 
dyspnea, chest pain, heartburn, and palpitations. We found a 
significant association between the number of nocturnal symp-
toms and sleep time: sleep time = 6.025 - 0.317 ×   number of 
nocturnal symptoms; R = -0.38, P , 0.0001.
Predictors of sleep quality and hrqOL
Bivariate predictors of HrQOL are shown in Table 5. On 
backwards stepwise multivariate analysis (Table 6), the 
independent significant predictors of SGRQ were education, 
HUI3, PSQI, and FEV1% (48% of the variance). For PSQI, 
the significant independent predictors were HUI3 and SGRQ 
(30% of the variance). For HUI3, the independent significant 
predictors were age, SGRQ, and PSQI (49% of the variance). 
The unique contribution of each independent variable on 
the variance of the dependent variable was expressed as the 
square of the semipartial correlation coefficient (Table 6). 
For the SGRQ, the PSQI uniquely contributes 5%, and for the 
HUI3, PSQI contributes 3% of the variance for the dependent   
variables.
Table 2 quality of life scores
HrQOL instrument Mean (SD) Median (25%–75%)
Sgrq  57.0 (21.3) 59.6 (41.7–75.6)
hUI3 0.52 (0.38) 0.62 (0.27–0.84)
PSqI  11.0 (5.4) 12.0 (6–16)
eSS 7.0 (4.8) 6.0 (3–9)
Sgrq Symptom domain 54.7 (25.4) 55.9 (33.3–75.7)
Sgrq Activity domain 67.4 (24.7) 72.6 (53.2–87.2)
Sgrq Impact domain 51.9 (22.9) 54.8 (34.2–69.4)
Pittsburgh .5 138 (77.7%)
eSS .9 44 (24.7%)
hrqOL and sleep quality according  
to gOLD class – mean (SD)
Mild (1) Moderate (2) Severe (3) Very severe (4)
  hUI3 0.40 (0.33) 0.58 (0.36) 0.53 (0.35) 0.39 (0.51)
  Sgrq 47.2 (16.5) 53.5 (24.5) 57.9 (20.3) 65.3 (20.8)
  PSqI 12.7 (3.2) 11.6 (4.8) 10.6 (5.6) 10.9 (5.6)
Note: The differences in hUI3, Sgrq and PSqI among gOLD classes were all nS (AnOVA).
Abbreviations: hrqOL, health-related quality of life; Sgrq, St georges respiratory questionnaire; hUI3, health Utilities Index 3; PSqI, Pittsburgh Sleep quality Index; 
eSS, epworth Sleepiness Scale. 
Table 3 Specific answers on the PSQI
Specific symptom/item Median (25%–75%)
Bedtime (clock time) 22:00 (22:45–02:00)
rise time (clock time) 06:00 (5:00–6:45)
Latency to sleep (min) 30.00 (2–45)
estimated sleep time (hours) 5 (4–6.5)
Symptoms or items  
$3 times per week
Number (%) reporting   
$3 times/week
Latency to sleep ,30 minutes 92 (51.7%)
Waken at night 133 (74.7%)
go to Br at night 134 (74.9%)
Can’t breathe at night 63 (35.2%)
Cough or snore loudly 85 (48.0%)
Think it is too cold 29 (16.2%)
Think it is too hot 66 (36.9%)
Bad dreams 19 (10.7%)
Feel pain at night 46 (25.7%)
Other problems  40 (22.2%)
Took sleep meds to help sleep 20 (11.1%)
Difficulty staying awake during  
activities in the day
12 (6.7%)
Snores loudly 55 (31.8%)
Witnessed apneas 38 (21.5%)
excessive movements of the legs 44 (24.6%)
nocturnal confusion 5 (2.8%)
restless sleep 56 (31.3%)
Other discomfort 45 (32.6%)
Snore/cough or witnessed apneas 74 (41%)
Snore/cough or WA + sleepy  
(“classic OSA”)
5 (2.8%)
Abbreviations: Br, bathroom; OSA, obstructive sleep apnea; PSqI, Pittsburgh Sleep 
quality Index; WA, witnessed apneas.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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We expressed the slope of the bivariate regression lines 
as the change in SGRQ in standard deviations for the whole 
group, against the change in the HrQOL index in standard 
deviations for the whole group. This standardized change is 
an indicator of the sensitivity of the outcome variable (SGRQ) 
relative to changes in the others. For a 1 SD change in PSQI, 
there was a 0.49 SD change in the SGRQ.
Table 7 shows the associations between specific 
medication categories and HrQOL. For the SGRQ, use of 
oral steroids, antibiotics, inhaled parasympathetic   blockers, 
and oral hypoglycemics was associated with improved 
HrQOL. For the PSQI, use of oral steroids and hypnotics 
was associated with improved sleep quality. Inhaled steroids 
Table 4 Specific night-time sleep symptoms (Sleep Symptom Questionnaire) and self-reported sleep time
Symptom Frequency  ,5 hours sleep $5 hours sleep Missinga P
nocturnal wheezing ,3 × per week 42 (40%) 61 (59%) 1 (1%) 0.0254
$3 × per week 46 (62%) 23 (31%) 5 (7%)
nocturnal cough ,3 × per week 37 (40%) 53 (47%) 3 (3%) nS
$3 × per week 51 (59%) 32 (37%) 3 (3%)
nocturnal dyspnea ,3 × per week 40 (47%) 46 (53%) 0 (0%) nS
$3 × per week 48 (53%) 37 (41%) 6 (7%)
nocturnal chest pain ,3 × per week 56 (45%) 65 (52%) 4 (3%) nS
$3 × per week 31 (60%) 19 (37%) 2 (4%)
nocturnal worry, 
depression, nervousness
,3 × per week
$3 × per week
48 (41%)
40 (66%)
68 (58%)
17 (28%)
2 (2%)
4 (7%)
0.0135
nocturnal lying awake 
with thoughts running 
through head
,3 × per week
$3 × per week
38 (38%)
50 (63%)
59 (60%)
26 (33%)
2 (2%)
4 (5%)
0.0167
nocturnal heartburn ,3 × per week 65 (45%) 76 (52%) 4 (3%) nS
$3 × per week 23 (68%) 9 (26%) 2 (6%)
nocturnal palpitations ,3 × per week 71 (47%) 77 (51%) 4 (3%) nS
$3 × per week 17 (63%) 8 (30%) 2 (7%)
Notes: expressed as number (percent of row). aMissing = no response, or responded “I don’t know”.
Table 6 Multivariate regression models
Variable Slope Semipartial 
R2
SE 
estimate
T P
Dependent variable: SGRQ
education  -0.73 0.03 0.23 -3.19 0.0017
hUI3  -23.00 0.12 3.72 -6.18 ,0.0001
PSqI  1.02 0.05 0.26 3.97 0.0001
FeV1% -0.21 0.02 0.08 -2.706 0.0075
Constant 74.77
Overall R2 0.48
Dependent variable: PSQI
hUI3 -4.43 0.06 1.14 -3.88 0.0002
Sgrq score 0.07 0.05 0.02 3.57 0.0005
Constant 9.07
Overall R2 0.30
Dependent variable: HUI3
Age  -0.01 0.07 0.002 -4.99 ,0.0001
Sgrq  -0.01 0.22 0.001 -8.60 ,0.0001
PSqI  -0.015 0.03 0.005 -3.25 0.0014
Constant 1.84
Overall R2 0.49
Abbreviations:  Sgrq,  St  georges  respiratory  questionnaire;  hU13,  health 
Utilities Index 3; PSqI, Pittsburgh Sleep quality Index; FeV1%, forced expired volume 
in 1 second as percent predicted.
Table 5 Bivariate regressions
Variable Intercept Slope Adjusted 
R2
P
Dependent variable: SGRQ
education (yrs) 70.63 -1.43 0.13 ,0.0001
hUI3 74.65 -33.86 0.37 ,0.0001
PSqI 35.95 1.93 0.23 ,0.0001
FeV1% 70.63 -0.29 0.04 0.0062
CCI 51.07 0.90 0.02 0.0473
Nonsignificant predictors: BMI, age, ESS
Dependent variable: PSQI
BMI (kg/m2) 7.05 0.15 0.017 0.0443
education (yrs) 12.53 -0.17 0.022 0.0271
hUI3 14.57 -6.92 0.239 ,0.0001
Sgrq  3.99 0.12 0.23 ,0.0001
CCI 8.8 0.33 0.04 0.0034
Nonsignificant predictors: age, ESS, FEV1%
Dependent variable: HUI3
education (yrs) 0.325 0.020 0.08 ,0.0001
Age (yrs) 1.008 -0.007 0.05 0.0023
Sgrq 1.147 -0.010 0.37 ,0.0001
PSqI 0.908 -0.035 0.24 ,0.0001
CCI 0.77 -0.04 0.12 ,0.0001
Not significant predictors: ESS, FEV1%, BMI
Abbreviations:  Sgrq,  St  georges  respiratory  questionnaire;  hU13,  health 
Utilities  Index  3;  PSqI,  Pittsburgh  Sleep  quality  Index;  FeV1%,  forced  expired 
volume in 1 second as percent predicted; CCI, Charlson Comorbidity Index; BMI, 
body mass index; eSS, epsworth Sleepiness Scale.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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were associated with worse sleep quality. For HUI3, oral 
steroids, antibiotics, and hypnotics were associated with 
improved HrQOL. Only 7.6% of the patients were taking 
antidepressants (data not shown), and use of these was 
not associated with differences in any measure of HrQOL. 
Finally, Table 2 shows the mean scores of HrQOL (HUI3 
and SGRQ) and sleep quality (PSQI) among the different 
GOLD class severities of COPD. None of the differences 
was significant.
Discussion
In this study of patients, most of whom had moderate to 
severe COPD, we found: 1) general and disease-specific 
HrQOL was low; 2) most patients experienced poor sleep 
quality (PSQI); 3) low sleep quality predicted low disease-
specific and generic HrQOL. There was no relationship 
either between the degree of airflow obstruction (FEV1%) 
and general HrQOL (HUI3) and sleep quality (PSQI) or 
between GOLD class and HrQOL or sleep quality. To our 
knowledge, this is the largest study available examining the 
relationship between sleep quality and general and disease-
specific HrQOL. In the ensuing discussion, we consider these 
findings in light of currently available literature.
hrqOL in COPD
Normative data for the HrQOL indices reported here do not 
exist for the Israeli population. Even with the most rigorous 
translation and validation procedures, scores from a given 
population may in part reflect cultural norms, and caution is 
urged in comparing different populations.
We reported a mean SGRQ score of 57.0, but others5,11,12 
have reported somewhat lower mean scores. Although we 
found that FEV1% was a significant correlate of SGRQ in 
both bivariate and multivariate models (Tables 5 and 6), we 
cannot attribute the lower scores reported by Nunes et al11 
to lower FEV1%, as this measure was similar to the one 
reported here. However, even with potential differences in 
cultural norms, the fact that within our group SGRQ scores 
were associated with FEV1% suggests that lung function is 
one determinant of COPD-specific HrQOL. On the other 
hand, neither the measure of HrQOL (HUI3, SGRQ) nor 
sleep quality (PSQI) was different among different GOLD 
severity classifications (Table 2). These data are consistent 
with the notion that self-assessed QOL is not necessarily 
predicted by the physiologic severity of airflow obstruc-
tion but is related to other factors, such as concomitant 
conditions, socioeconomic factors, education, and cultural 
factors.
The HUI3 has not been extensively evaluated in COPD. 
We found a mean score of 0.52. This is lower than sleep 
disorders patients18 and considerably lower than nor-
mal population values of 0.86 to 0.9.28,29 Our values are 
even lower than means from the datasets of Shaya et al 
and Sawka et al.30,31 By way of comparison, our patients 
have HUI3 scores comparable with patients recovering 
from stroke and with arthritis, and even lower than those 
reported in survivors of advanced neuroblastoma and 
Wilms’ tumor.28,32 Thus, COPD imparts a heavy burden on 
general HrQOL.
As measured by the PSQI, 77.7% of the patients 
reported disturbed sleep (PSQI . 5), with long latencies 
to sleep (median 30 minutes) and short sleep times (median 
5 hours). There was a large discrepancy between self-
reported time in bed (8 hours) and the self-reported sleep 
times. This suggests a fair amount of wake after sleep onset 
and resultant sleep fragmentation. This is consistent with 
the finding that approximately three-quarters of the patients 
reported nocturnal awakenings. Future studies could be 
directed to objective assessment of sleep   fragmentation 
in COPD.
Table 7 Medication classes associated with differences in selected Sgrq, PSqI, and hUI3
Medication HrQOL index Mean (SD) of those taking Mean (SD) of those not taking P
Oral steroids Sgrq 52.2 (21.0) 68.6 (18.8) ,0.0001
Antibiotics Sgrq 52.9 (20.8) 64.2 (20.0) 0.0005
Inhaled parasympathetic 
blockers
Sgrq 53.5 (21.0) 60.0 (21.0) 0.0424
Oral hypoglycemics Sgrq 55.7 (21.6) 64.3 (18.2) 0.0409
Oral steroids PSqI 10.4 (5.3) 12.3 (5.3) 0.03
Inhaled steroids PSqI 12.1 (5.4) 10.3 (5.2) 0.0353
hypnotics PSqI 10.5 (5.4) 13.7 (3.4) 0.0037
Oral steroids hUI3 0.58 (0.36) 0.38 (0.39) 0.0012
Antibiotics hUI3 0.58 (0.36) 0.41 (0.40) 0.0061
hypnotics hUI3 0.54 (0.37) 0.37 (0.44) 0.0358
Abbreviations: Sgrq, St georges respiratory questionnaire; PSqI, Pittsburgh Sleep quality Index; hU13, health Utilities Index 3; hrqOL, health-related quality of life.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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It should be noted that the PSQI is a score of self-rated 
quality of sleep and not a measure of sleep-related HrQOL, 
such as the Functional Outcomes of Sleep Quality score.33 
The mean PSQI score reported here is greater (ie, rated worse) 
than that previously reported in COPD.11,12 It is not clear 
why this should be so. The extent of airflow obstruction as 
measured by FEV1% in the cited studies was similar to ours. 
However, comorbidity burden was not reported in the other 
studies. In our study, comorbidity burden (CCI) was a bivari-
ate predictor of PSQI, although not significant on multivariate 
analysis. Possibly, the comorbidity burden in our patients was 
greater than in the other reports, influencing the estimation of 
sleep disturbances. Finally, the PSQI combines the symptoms 
of coughing and snoring in one question. It is possible that 
patients answering this question would actually overestimate 
the frequency of snoring by combining this symptom with 
coughing. In the Sleep Symptom Questionnaire, the symptom 
of nocturnal coughing was given by itself, and the prevalence 
was similar to that of “cough and snore” on the PSQI (Tables 3 
and 4). This gives credence to the idea that the PSQI cannot 
be used to distinguish snore as a sign of sleep apnea from 
coughing when associated with COPD.
Interestingly, excessive sleepiness, as assessed by the ESS, 
was not a prominent part of the symptomotology in most 
patients, even though many reported disturbed sleep as judged 
by long sleep latency, short sleep time, and being unable to 
remain asleep. Thus, insomnia without excessive sleepiness 
was the primary sleep complaint reported by our patients. 
The reasons for the dissociation between short self-reported 
sleep times and lack of excessive sleepiness in many patients 
are not clear. However, the association between ESS scores 
and severity of disease in organic sleep disorders, such as 
OSA or objective measures of sleepiness, is not close, and the 
ESS may not reflect objective sleepiness.34 Cultural norms, 
difficulties with recall, and not wishing to acknowledge that 
one is sleepy can influence the ESS. It is also possible that 
medication use, sympathetic hyperstimulation, or anxiety 
could induce a “hyper alert” state, thereby diminishing the 
extent of excessive sleepiness and fragmenting sleep.
The presence of the classic symptoms as a sign of sleep 
apnea (snoring and/or witnessed apneas and daytime sleepi-
ness) was rare in our patients, although approximately 15% 
were known to have OSA. The causes of insomnia in COPD 
are likely multifactorial. Anxiety and depression are common 
problems in patients with COPD, and HrQOL is correlated 
with depression/insomnia scores.12 Although few in our 
cohort were taking antidepressants, depression/anxiety may 
have been unrecognized by these patients or their physicians. 
Other reasons for disturbed sleep could relate to the effects of 
nocturnal hypoxia/hypercarbia.6,7 Finally, as indicated below, 
medications used with COPD can affect sleep.
We showed no association between sleep quality (PSQI) 
or disease-specific (SGRQ) quality of life with age, as might 
be expected. Possibly, mean age was too high or age vari-
ability was too low. Alternatively, it may be that the effects 
of moderate to severe disease on QOL overwhelm any effects 
of age. In addition, although there was a bivariate association 
between CCI and QOL indices (Table 5), CCI did not remain 
as an independent predictor in the multivariate analyses 
(Table 6). It may be that components of the CCI themselves 
influence both sleep quality and QOL in variable ways.
Medication use
A number of medications used by COPD patients could 
potentially affect sleep quality. As seen in Table 7, most 
medication classes were associated with improved HrQOL 
and sleep quality. The exception was that inhaled steroids 
were associated with worse sleep quality (PSQI). It is not 
clear why this should be so. One interpretation is that use of 
the most common medications, including those for treatment 
of COPD, improves airflow or stabilizes airways at night, 
thus improving sleep quality. Possibly, the use of inhaled 
steroids, often given to minimize or eliminate the need for 
oral steroids, results in less effective stabilization of airway 
inflammation at night.
COPD medications are often thought by clinicians to 
  fragment sleep. However, this has been difficult to document, 
as previous studies have not reported consistent worsening of 
sleep quality with some commonly used medication classes 
in COPD. Veale et al35 noted no change in sleep quality in 
14 patients with COPD treated with a sustained-release form 
of salbutamol. The effects of theophylline on sleep quality 
have been more variable, with some studies demonstrating 
an impairment in sleep quality,36 whereas others have noted 
no significant effect.37 Anticholinergics, such as ipratropium, 
may improve sleep quality.38 More recently, McNicholas 
et al39 demonstrated that the long-acting anticholinergic 
tiotropium did not affect sleep quality after four weeks of 
treatment. Finally, there are few data available on the effects 
of oral steroids on sleep quality in COPD.
It is possible that COPD patients are “hyper alert” 
and do not have excessive daytime sleepiness in spite 
of reduced sleep time due to sympathetic hyperstimula-
tion associated with airway obstruction, hypoxia, or 
  medications. Regarding the latter, we found no association 
with   methylxanthine use or inhaled beta-agonist use, agents International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8
Scharf et al
that increase alertness. We did find that oral steroids and 
hypnotics were associated with changes in PSQI but in the 
direction of improved sleep quality, whereas inhaled steroids 
were associated with worse HrQOL. Use of oral steroids and 
antibiotics suggests the   possibility of COPD exacerbation 
within the quarter (but not the month) prior to the survey, 
and this could have influenced HrQOL. Hypnotic use was 
associated with improved sleep quality, although worsening 
HUI3. The use of hypnotics could improve sleep quality but 
worsen general HrQOL if there are carryover effects the next 
day. We believe that the use of hypnotics in COPD patients 
with insomnia should be further explored.
Associations between measures  
of sleep quality and hrqOL
The PSQI was a significant and independent predictor of 
disease-specific (SGRQ) and general HrQOL (HUI3). The 
FEV1% was correlated with SGRQ but not with HUI3. The 
correlation between SGRQ and FEV1% suggests that many 
symptoms recorded in the SGRQ are functions of the degree 
of airflow obstruction. These findings differ somewhat from 
previous studies in younger asthmatics23 in which the FEV1% 
was not a predictor of indices of asthma-related HrQOL. On 
the other hand, in asthmatics, as in our study, the PSQI was 
an independent predictor of HrQOL.23 Our studies confirm 
and extend previous smaller studies11,12 showing that sleep 
quality predicts overall and disease-specific HrQOL. Hence, 
it appears that sleep quality should be taken into account 
when considering HrQOL in COPD trials.
Study limitations
The survey methodology used here may be subject to recall 
bias. This is true of any surveys relying on patient recall. We 
attempted to minimize this by keeping the recall period to four 
weeks, but it must be acknowledged as a study   limitation. We 
also attempted to minimize bias by using trained interview-
ers to administer the surveys.40 This study gathered data on 
medication use and comorbidity retrospectively from a data-
base. We cannot ascertain whether patients actually took the 
medication they were issued, nor can we know if there were 
other comorbid conditions present that were not recorded. We 
also cannot objectively determine the prevalence of organic 
sleep disorders, such as OSA, as few underwent sleep testing. 
Additionally, nocturnal oxygen desaturation could contrib-
ute to nocturnal sleep disturbances. In our clinically stable 
patients, daytime oxygen saturations on room air were quite 
high. However, we have no data on nocturnal oxygenation 
in this group of patients. Future studies of quality of life and 
sleep disturbances should incorporate this important measure. 
We would point out that we excluded patients who had an 
exacerbation within the four weeks   preceding the question-
naire. We acknowledge that   symptoms from exacerbation 
can last for several months after this. Thus, it is possible that 
QOL in some patients reflects an exacerbation prior to the 
four-week period. Finally, we would point out that although 
sleep quality contributes to HrQOL in these patients, there 
are other, unmeasured, factors that likely contribute to QOL. 
In addition to what has been discussed previously, these 
include mental health issues (state of depression, anxiety), 
physiologic changes (hypoventilation at night), concomitant 
illnesses, family factors, and others. The fact that the sleep 
QOL measure (PSQI) contributed only 3%–5% of the vari-
ance (Table 6) to the different HrQOL indices indicates that 
other, unmeasured, factors likely play a role in determination 
of HrQOL in COPD patients.
Conclusion
Patients with COPD have poor HrQOL and a high   prevalence 
of disturbed sleep. This was correlated with indices of 
  disturbed sleep. Few patients reported daytime sleepiness 
in spite of severe sleep disturbances. Studies in COPD 
  incorporating HrQOL as an outcome should take sleep 
  quality into account.
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Methods supplement
questionnaire validation  
and reliability testing
The questionnaires included the Health Utilities Index (HUI), 
Pittsburgh Sleep Quality Index (PSQI), St George’s Respiratory 
Questionnaire (SGRQ), and a convenience questionnaire we 
have called the Sleep Symptom Questionnaire. We used 
a previously validated Hebrew version of the Epworth 
Sleepiness Scale (ESS) that is currently in use at the sleep 
laboratory of the Soroka University Medical Center. For 
this study, the HUI, PSQI, SGRQ, and Sleep Symptom 
Questionnaire were independently translated into Hebrew 
by two bilingual native Hebrew speakers with medical 
expertise. The Hebrew versions were then reviewed by one 
of the translators, a practicing Israeli pulmonologist, and 
merged into a single document that was reviewed again. 
Translators were instructed to base the translations on the 
intent of the question, not the literal meaning, to make the 
questions culturally meaningful and to attempt to translate at 
approximately the sixth grade level. The translated documents 
were then independently translated back into English by two 
bilingual native English speakers with medical expertise 
who had not been involved in the original translation. The 
back-translated version was reviewed by a member of our 
team (SMS) who was not on either translation committee. 
Discrepancies between the original English and the back-
translated versions were brought to the attention of the 
translation committees for reconciliation.
Test–retest reliability was also examined by readminister-
ing the questionnaires to 15 participants within two months 
of their original questionnaire submission, and the results 
between the two sets were compared using paired t-tests. 
There were no statistically significant differences between 
the HUI, PSQI, SGRQ, and the previous Hebrew version of 
the ESS administered at the two time points.
The reliability and internal consistency of the Hebrew 
version of the scales were examined using Cronbach’s alpha.41 
The Cronbach’s alpha for the HUI3 was 0.818 and compared 
well to a random selection of chronic obstructive pulmonary 
disease (COPD) patients from a previous American study30 
with Cronbach’s alpha = 0.837. The Cronbach’s alpha for 
the PSQI was 0.746. We did not have a previous data set 
with which to compare this. The Cronbach’s alpha for the 
SGRQ was 0.916 and compared favorably with a random, 
anonymized selection of COPD patients from a previous 
American study (courtesy John Connett, University of 
Minnesota; Cronbach’s alpha = 0.815). For the questions on 
the Sleep Symptom Questionnaire, the alpha was 0.911. An 
alpha of $ 0.7 is generally considered acceptable for group 
comparisons.42
Patients and setting
The study was performed at the Pulmonary Clinic of the 
Soroka University Medical Center in Beer Sheba, Israel. This 
is a large (1000 bed) tertiary care academic medical center 
and is the major clinical affiliate of the Faculty of Health 
Sciences, Ben-Gurion University. The Soroka University 
Medical Center Ethics Committees approved the protocol.
This questionnaire survey was performed from February 
2009 to December 2010 on a convenience sample of patients 
coming to the pulmonary clinic for routine follow-up with a 
diagnosis of COPD made by one of the pulmonary specialists. 
A total of 200 patients were approached to participate and 180 
agreed. Inclusion criteria were: 1) age . 35 years; 2) smoking 
history of at least 10 pack-years; 3) COPD previously 
diagnosed by a pulmonary specialist based on history of 
smoking, airflow obstruction on spirometry, and the presence 
of at least one symptom of COPD (ie, exercise-limiting 
dyspnea, chronic cough, sputum production); 4) stability of 
disease defined as no exacerbations within at least one month; 
5) no history of hospitalization or urgent care visit within 
one month for any other reason; and 6) sufficient knowledge 
of Hebrew to give informed consent, to understand the 
questions, and to give answers. Exclusion criteria were: 
1) another major pulmonary diagnosis, including asthma, 
bronchiectasis, and pulmonary fibrosis; or 2) the presence 
of disease expected to shorten life span to less than three 
years. All questionnaires were for one month recall and were 
administered face to face by trained interviewers.
Lung function
Spirometric indices of lung function were obtained on the 
day of questionnaire administration according to standards 
set by the American Thoracic Society.13 These included forced 
vital capacity (FVC), forced expired volume in one second 
(FEV1), and the ratio FEV1/FVC. COPD severity was staged 
according to the Global Initiative for Lung Disease (GOLD) 
2006 guidelines.14
Demographic information
Patient age, gender, body mass index (BMI), current smoking 
status (current, ex-smoker [defined as no smoking for at least 
one month]), and pack-years smoking were ascertained on 
the day of the interview.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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Socioeconomic status
The subjects were asked four questions regarding their socio-
economic status: 1) income relative to the Israeli average of 
8000 NIS per month (much lower, lower, equal to, higher, 
much higher); 2) years of schooling; 3) employment status 
(employed, unemployed, on pension); and 4) marital status 
(married, divorced, widowed, separated, bachelor/ette).
Questionnaires
generic hrqOL instrument
health Utilities Index (hUI)
The HUI system16,17 represents a generic quality of life (QOL) 
measurement that includes two active systems, known as the 
HUI2 and HUI3. Both separately, but in a complementary 
manner, classify health status and establish a preference-based 
scoring system. The attributes of the HUI2 include sensation, 
mobility, emotion, cognition, self-care, pain, and fertility. Each 
of these attributes has three to five levels (ie, descriptions of 
health status worded directly in the questionnaire). Similarly, 
the HUI3 consists of eight attributes with five to six levels each. 
The attributes of the HUI3 include vision, hearing, speech, 
ambulation, dexterity, emotion, and cognition. Although sev-
eral attributes within the HUI2 and HUI3 appear to be similar 
and to encompass overlapping disease states, all attributes were 
designed to be structurally independent. Together, the HUI2 
and HUI3 measures account for approximately one million 
individual health states. This is possible because each attribute 
within the HUI2 or HUI3 exists independently of the others, 
and levels within each attribute do not affect the levels within 
other attributes. The 17-point HUI2/3 questionnaire is scored 
with a formula in accordance with von Neumann–Morganstern 
utility theory.43 The questionnaire has been validated in 14 
languages,32,44 has recall periods of one, two, and four weeks, 
and a usual long-term health follow-up. Therefore, the survey 
can be used in a wide variety of patients to assess HrQOL 
over several time periods. The utility score (a score measur-
ing patient preference for one disease state over another) for 
a population of patients is expressed from 0.0 to 1.00 (perfect 
health). Where the HUI is concerned, disease states, rated as 
worse than death (eg, -0.3) are possible. The HUI2, in part, 
derives from answers on the HUI3 and was highly correlated 
with it (R = 0.88). All correlations seen with the HUI3 were 
also seen with the HUI2. In the present study, little additional 
information was gained by inclusion of the HUI2. Hence, for 
simplicity, we present only the HUI3 scores in this study. The 
HUI system was recently validated against a population of 
patients with sleep disorders.18
Disease-specific HrQOL instrument
COPD-specific: St George’s Respiratory 
questionnaire
The SGRQ is designed to measure the impact of respiratory 
disease on HrQOL and well-being.19 Responses to its 53 items 
are expressed as an overall score in the domains symptoms, 
activity, and impact. The scores range from 0% (best) to 
100% (worst). Previous results provide strong evidence that 
the SGRQ is valid and responsive.19,20
Instruments rating sleep quality
Pittsburgh Sleep quality Index (PSqI)
This is a 19-item self-rating scale designed to measure 
perceived quality of sleep. The components are weighted 
and a global score of 0–21 is derived, with increasing score 
meaning worse sleep quality. A global score of .5 is accepted 
as differentiating good from poor sleepers.21
epworth Sleepiness Scale
In this metric, the subject is asked to rate the probability 
of falling asleep on a scale of increasing probability from 
0 to 3 in eight different situations.22 The scores for the eight 
questions are added to obtain a single number. A number in 
the range 0–9 is considered normal, whereas a number in the 
range 10–24 indicates excessive sleepiness and the need for 
referral to a sleep specialist.
Sleep Symptom questionnaire23
The Sleep Symptom Questionnaire (Figure 1) was originally 
used to elicit specific nocturnal symptoms in a study of 
HrQOL in patients with asthma and consists of eight 
questions about the frequency of specific respiratory and 
nonrespiratory symptoms at night. The respiratory symptoms 
include wheezing, cough, dyspnea, and chest pains. The 
nonrespiratory symptoms include heartburn, worry/anxiety, 
intrusive thoughts, and palpitations. There is no weighting 
of answers and no composite score is generated. Answers to 
each question are given as the frequency of these symptoms 
in nights per week.
Comorbidity burden
The comorbidity burden has been shown to be a determinant 
of health care utilization in COPD.24 Accordingly, data 
on selected comorbidities were collected from the central 
database of the major health maintenance organization in 
Israel, the Clalit Health Services. Comorbidity burden was 
measured using the age-adjusted Charlson Comorbidity Index International Journal of COPD
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(CCI) with the Deyo modification.25,26 The CCI originally was 
developed as a risk measure of one-year mortality rate based 
on hospital chart abstraction, but it has been adapted for use 
with International Classification of Disease (ICD)-9 diagnostic 
codes.27 The CCI contains 17 categories of comorbidities with 
each assigned a weight of 1, 2, 3, or 6, reflecting the magnitude 
of the adjusted relative risks associated with each comorbidity. 
The CCI score then sums the weights for all conditions with 
a total maximum score of 33. We also recorded whether 
patients had previously undergone formal sleep testing or had 
a diagnosis of concomitant obstructive sleep apnea (OSA), 
whether they had undergone evaluation for treatment with 
continuous positive airway pressure (CPAP), and whether 
this treatment had been ordered.
Medication use
We obtained data on specific medication categories issued 
to the patients in the quarter prior to the administration of 
the questionnaires from the database of the Clalit Health 
Services. The categories of medication were listed accord-
ing to the World Health Organization (WHO) drug listing. 
The categories and WHO classification numbers were as 
follows: inhaled beta-agonists (R03 AC), inhaled steroids 
(R03BA), inhaled antiparasympathetics (R03BB), antileu-
kotrienes (R03DC), methylxanthines R03DA), antibiotics 
(J01), systemic steroids (H02 AB), chemotherapy (L01), 
ACE inhibitors (C09 A), diuretics (C03), antidepressants 
(N06 A), antipsychotics (N05 A), beta-blockers (C07), 
statins (C10 AA), insulin (A10 A), oral hypoglycemics 
(A10B), hypnotics (N05C), digoxin (C01 AA05), opiates 
(R05D), and calcium channel blockers (C08). Individuals 
taking combination inhalers (eg, inhaled steroid, inhaled 
beta agonist combination) were coded as taking each of the 
components.
Data on comorbidity burden and medication use could 
not be gathered on three of the patients because they were not 
members of Clalit Health Services. Thus, data on comorbidity 
burden and medication use represent 177 patients. All 
other data, however, could be collected on the entire cohort 
(n = 180).
Data analysis
Data were compiled and expressed as mean ± standard 
deviation (SD), as well as median and 25th and 75th 
percentiles. To establish associations between variables, 
Pearson product-moment coefficients were calculated. 
Regression analysis was carried out using the least-squares 
technique. Significant bivariate associations were then entered 
into a backwards stepwise multivariate regression model to 
determine significant predictors of assigned independent vari-
ables. Differences between means were tested using Student’s 
t-test for unpaired variates. In the rare case when data were 
not normally distributed (Kolmogorov–Smirnoff test), the 
Mann–Whitney U test was used to determine statistical 
significance. Rates and proportions were tested using the 
Chi-square test. The null hypothesis was rejected at the 5% 
level. Differences in indices of HrQOL with different levels 
of COPD severity (GOLD) were tested using one-factor 
analysis of variance (ANOVA), data analysis was performed 
using Statistical Package for the Social Sciences, version 
17 (SPSS Inc, Chicago, IL, USA) or GBstat v9 (Dynamic 
Microsystems Inc, Silver Spring, MD, USA).